NewcelX Ltd. NCEL
2.72 USD -0.17 (-5.73%)
At closeNov 6, 2026, 4:00 PM EST
2.76 +0.04 +1.31%
After hours · Nov 6, 4:00 PM ET
2.65 Day range 2.80
1.83 52-week range 5.12
- YTD
- +43.39%
- 1 year
- -34.35%
- Market cap
- 15.74M
- EPS (ttm)
- 0.52
- P/E ratio
- 5.24
- YTD return
- +43.39%
- 1-year return
- -34.35%
- Volume
- 11.24K
- Avg volume
- 13.18K
- Open
- 2.80
- Previous close
- 2.89
- Day's range
- 2.65 – 2.80
- 52-week range
- 1.83 – 5.12
5Y -845.28 (-99.68%)
Financials — quick view
NCEL Revenue — annual 0
NCEL Net income — annual -8.30M
NCEL EPS — annual -2.16
News
12 Health Care Stocks Moving In Friday's Pre-Market Session 
NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
12 Health Care Stocks Moving In Thursday's Pre-Market Session - 12 Health Care Stocks Moving In Friday's Pre-Market Session
NewcelX Issued Patent From Brazilian Patent And Trademark Office For Its Nnovative Cell Selection And Enrichment Technology 
Laidlaw & Co. Initiates Coverage On NewcelX with Buy Rating, Announces Price Target of $23 
NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed Strategy 
NewcelX Announces Publication Of Peer-Reviewed Study On The Potential Of AstroRx, A Human Embryonic Stem Cells-Derived Astrocyte Therapy, In The Journal Stem Cell Reports 
EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND Submission
Your note
Sign in to keep a note on NCEL — it syncs with the Stock Master app.